Literature DB >> 17000885

Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease.

Jan Jacques Michiels1, Zwi Berneman, Alain Gadisseur, Marc van der Planken, Wilfried Schroyens, Ann van de Velde, Huub van Vliet.   

Abstract

All variants of type 2 von Willebrand disease (VWD) patients, except 2N, show a defective von Willebrand factor (VWF) protein (on cross immunoelectrophoresis or multimeric analysis), decreased ratios for VWF:RCo/Ag and VWF:CB/Ag and prolonged bleeding time. The bleeding time is normal and FVIII:C levels are clearly lower than VWF:Ag in type 2N VWD. High resolution multimeric analysis of VWF in plasma demonstrates that proteolysis of VWF is increased in type 2A and 2B VWD with increased triplet structure of each visuable band (not present in types 2M and 2U), and that proteolysis of VWF is minimal in type 2C, 2D, and 2E variants that show aberrant multimeric structure of individual oligomers. VWD 2B differs from 2A by normal VWF in platelets, and increased ristocetine-induced platelet aggregation (RIPA). RIPA, which very likely reflects the VWF content of platelets, is normal in mild, decreased in moderate, and absent in severe type 2A VWD. RIPA is decreased or absent in 2M, 2U, 2C, and 2D, variable in 2E, and normal in 2N. VWD 2M is usually mild and characterized by decreased VWF:RCo and RIPA, a normal or near normal VWF multimeric pattern in a low resolution agarose gel. VWD 2A-like or unclassifiable (2U) is distinct from 2A and 2B and typically featured by low VWF:RCo and RIPA with the relative lack of high large VWF multimers. VWD type 2C is recessive and shows a characteristic multimeric pattern with a lack of high molecular weight multimers, the presence of one single-banded multimers instead of triplets caused by homozygosity or double hereozygosity for a mutation in the multimerization part of VWF gene. Autosomal dominant type 2D is rare and characterized by the lack of high molecular weight multimers and the presence of a characteristic intervening subband between individual oligimers due to mutation in the dimerization part of the VWF gene. In VWD type 2E, the large VWF multimers are missing and the pattern of the individual multimers shows only one clearly identifiable band, and there is no intervening band and no marked increase in the smallest oligomer. 2E appears to be less well defined, is usually autosomal dominant, and accounts for about one third of patients with 2A in a large cohort of VWD patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17000885     DOI: 10.1177/1076029606293422

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  13 in total

Review 1.  Laboratory testing for von Willebrand disease: toward a mechanism-based classification.

Authors:  Richard Torres; Yuri Fedoriw
Journal:  Clin Lab Med       Date:  2009-06       Impact factor: 1.935

2.  Quantitative Age-specific Variability of Plasma Proteins in Healthy Neonates, Children and Adults.

Authors:  Stefan Bjelosevic; Dana Pascovici; Hui Ping; Vasiliki Karlaftis; Thiri Zaw; Xiaomin Song; Mark P Molloy; Paul Monagle; Vera Ignjatovic
Journal:  Mol Cell Proteomics       Date:  2017-03-23       Impact factor: 5.911

Review 3.  Acquired von Willebrand syndrome associated with left ventricular assist device.

Authors:  Angelo Nascimbene; Sriram Neelamegham; O H Frazier; Joel L Moake; Jing-Fei Dong
Journal:  Blood       Date:  2016-05-03       Impact factor: 22.113

4.  G protein-dependent basal and evoked endothelial cell vWF secretion.

Authors:  Luiza Rusu; Alexandra Andreeva; David J Visintine; Kyungho Kim; Stephen M Vogel; Aleksandra Stojanovic-Terpo; Olga Chernaya; Guoquan Liu; Farnaz R Bakhshi; Sandra L Haberichter; Hiroko Iwanari; Osamu Kusano-Arai; Nobuchika Suzuki; Takao Hamakubo; Tohru Kozasa; Jaehyung Cho; Xiaoping Du; Richard D Minshall
Journal:  Blood       Date:  2013-09-30       Impact factor: 22.113

5.  Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D'D3 and D4 domains.

Authors:  Monica Sacco; Stefano Lancellotti; Mattia Ferrarese; Francesco Bernardi; Mirko Pinotti; Maira Tardugno; Erica De Candia; Leonardo Di Gennaro; Maria Basso; Betti Giusti; Massimiliano Papi; Giordano Perini; Giancarlo Castaman; Raimondo De Cristofaro
Journal:  Blood Adv       Date:  2020-07-28

6.  Age-related differences in plasma proteins: how plasma proteins change from neonates to adults.

Authors:  Vera Ignjatovic; Cera Lai; Robyn Summerhayes; Ulrike Mathesius; Sherif Tawfilis; Matthew A Perugini; Paul Monagle
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

7.  Identification and functional analysis of a novel von Willebrand factor mutation in a family with type 2A von Willebrand disease.

Authors:  Jing Dong; Xiaojuan Zhao; Sensen Shi; Zhenni Ma; Meng Liu; Qingyu Wu; Changgeng Ruan; Ningzheng Dong
Journal:  PLoS One       Date:  2012-03-27       Impact factor: 3.240

8.  Phenotypic and genetic characterizations of the Milan cohort of von Willebrand disease type 2.

Authors:  Omid Seidizadeh; Luciano Baronciani; Maria Teresa Pagliari; Giovanna Cozzi; Paola Colpani; Andrea Cairo; Simona Maria Siboni; Eugenia Biguzzi; Flora Peyvandi
Journal:  Blood Adv       Date:  2022-07-12

9.  Perioperative onset of acquired von Willebrand syndrome: Comparison between HVAD, HeartMate II and on-pump coronary bypass surgery.

Authors:  Christina Feldmann; Rashad Zayat; Andreas Goetzenich; Ali Aljalloud; Eva Woelke; Judith Maas; Lachmandath Tewarie; Thomas Schmitz-Rode; Ruediger Autschbach; Ulrich Steinseifer; Ajay Moza
Journal:  PLoS One       Date:  2017-02-24       Impact factor: 3.240

10.  Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis.

Authors:  Chad K Heazlewood; Matthew C Cook; Rajaraman Eri; Gareth R Price; Sharyn B Tauro; Douglas Taupin; David J Thornton; Chin Wen Png; Tanya L Crockford; Richard J Cornall; Rachel Adams; Masato Kato; Keats A Nelms; Nancy A Hong; Timothy H J Florin; Christopher C Goodnow; Michael A McGuckin
Journal:  PLoS Med       Date:  2008-03-04       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.